Visceral leishmaniasis (VL) has emerged as an opportunistic infection in HIV-infected patients in Mediterranean area; particularly in patients with CD4 lymphocyte counts p200 Â 10 6 /l. 1,2 It has been described after organ transplantation, 3 but not after HSCT. A 57-year-old male underwent an HLA-matched peripheral blood stem cell transplant following a dose-reduced conditioning regimen for AML (TBI 6 Gy, cyclophosphamide 60 mg/kg and ATG 10 mg/kg). At 10 weeks after transplantation, the patient developed grade IV corticosteroid-resistant acute GVHD requiring multiple immunosuppressive drugs including ATG, anti-CD25 monoclonal antibody and mycophenolate mofetil. Immunosuppressive therapy was eventually discontinued 119 weeks post transplant. Table 1 summarizes the clinical course. Fever occurred 66 weeks post transplant. Physical examination was normal. Invasive aspergillosis was suspected based upon a pulmonary nodule and the detection of Aspergillus antigen in the peripheral blood, and treated with an amphotericin B lipid complex (Abelcet 5 mg/kg/day for 1 month), followed by itraconazole. Fever recurred 94 weeks post transplantation. Despite treatment with caspofungin, fever persisted and the pulmonary nodule was surgically removed. Pathological analysis confirmed the presence of Aspergillus. The extensive investigation for unexplained persisting fever led, at week 117, to the diagnosis of VL upon detection of specific antibodies by immunofluorescence antibody test (IFAT, positive at 1/5120) and ELISA. Western blot (WB) analysis confirmed the diagnosis with antibodies directed against five antigens (14, 18, 21, 23 and 31 kDa). 4 Retrospective serological analysis revealed that, during the first episode of fever, the patient had acquired the profile of an asymptomatic carrier, characterized by a negative serology by IFAT and ELISA analysis and antibodies directed against a 18-kDa protein on WB. Reactivation of latent disease occurred just before the second episode of fever. The diagnosis of VL was confirmed by the isolation of numerous Leishmania amastigotes in the bone marrow aspirate and in peripheral blood after leukocyte concentration. Culture of bone marrow yielded Leishmania promastigotes, and isoenzymatic characterization identified Leishmania infantum MON-1 (WHO Collaborative Centre, Montpellier, France). Review of bone marrow aspirates performed at weeks 71 and 87 weeks post transplantation showed rare amastigotes, previously undiagnosed. Analysis of donor and recipient pretransplant sera by WB revealed no Leishmania-specific antibodies, and detection of parasite DNA by PCR analysis in peripheral blood was negative, prior to transplantation in both individuals. Treatment consisted in a 22 mg/kg total dose of liposomal amphotericin B (4 mg/kg from day 1 to day 5 and 2 mg/kg at day 12: the last dose was reduced due to treatment-related renal failure). Fever ceased on day 3 of therapy and detection of parasite DNA by PCR analysis in peripheral blood was negative after the end of treatment.
The next 14 months of follow-up were uneventful. VL may result from either a primary Leishmania infection or reactivation of a latent infection, which may have been acquired many years before. 5 Contamination by Leishmania was asymptomatic in our patient and could roughly be dated between the 60th and the 66th weeks. The three potential sources of Leishmania transmission after HSCT could have the graft itself, blood products from healthy carriers, or a sandfly bite, the latter being the most probable cause in our patient who lived in an endemic area. 6 The patient had not received any transfusion for many months. The clinical spectrum of VL varies, possibly delaying the diagnosis, particularly in immunocompromised hosts. 3, 7 The detection of antibodies to Leishmania by the IFAT or ELISA technique is a useful diagnostic tool in patients able to product a significant increase in antiLeishmania antibody titer. WB has a higher sensitivity and discriminates between primary infection and reactivation of a latent infection. 8 Finally, the diagnosis relies on the detection of amastigotes in bone marrow or even in peripheral blood by leukocyte concentration, although the parasites may be so scanty that they are not detected. 9 The detection of parasite DNA by PCR in peripheral blood is a very sensitive technique for both diagnosis and follow-up of treatment efficacy, in contrast to serology which remains positive for a long time. 10 Although no large-scale study with amphotericin B lipid formulations has been reported, and despite its higher cost when compared to pentavalent antimony, liposomal amphotericin B is presently the first-line therapy recommended in immune-suppressed patients.
11 Nevertheless, precise treatment strategies and particularly the need of a secondary chemoprophylaxis remain to be determined. VL should be considered as an opportunistic infection in hematopoietic stem-cell-transplanted patients, and more largely in all immunosuppressed transplanted recipients living in endemic areas for Leishmania. As already performed for Toxoplasma gondii, identification of Leishmania carriers by WB analysis prior to transplantation would detect patients at risk for Leishmania reactivation during periods of maximal immunosuppression, and lead to earlier diagnosis. Outside endemic areas, VL should be systematically considered in transplanted patients with persisting unexplained fever and a history of travel to an endemic zone.
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